NEW YORK (GenomeWeb) – Startup MiR Diagnostics has begun laying the groundwork for a prospective study to validate its ncRNA-based test for differentiating indolent from aggressive prostate tumors, with the goal of launching the diagnostic in mid- to late 2018.

The study is expected to evaluate the test's performance in tumor samples obtained from up to 2,000 patients at multiple clinical centers in the US, company Co-founder and CSO Martin Tenniswood told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.